Stimdia Medical
Stimdia Medical is dedicated to developing innovative medical technologies that expedite ventilator weaning and patient liberation. Founded in September 2015 out of the University of Minnesota, the company focuses on neuromodulation solutions, including the pdSTIM System, to improve ICU patient management and reduce healthcare costs. Led by a team of experts and supported by strategic investors, Stimdia aims to transform critical care medicine through its advanced neurostimulation devices.
Industries
Nr. of Employees
small (1-50)
Patents
Electrical stimulation for preservation and restoration of diaphragm function
US-11052250-B2
View DetailsElectrical stimulation for preservation and restoration of diaphragm function
US-10300272-B2
View DetailsElectrical stimulation for preservation and restoration of diaphragm function
US-10293157-B2
View DetailsElectrical stimulation for preservation and restoration of diaphragm function
US-9682235-B1
View Details
Electrical stimulation for preservation and restoration of diaphragm function
US-11052250-B2
View DetailsElectrical stimulation for preservation and restoration of diaphragm function
US-10300272-B2
View DetailsElectrical stimulation for preservation and restoration of diaphragm function
US-10293157-B2
View DetailsElectrical stimulation for preservation and restoration of diaphragm function
US-9682235-B1
View DetailsProducts
Percutaneous phrenic nerve stimulation system (console and lead therapy set)
A therapy system composed of a stimulation console and temporary percutaneous multielectrode leads placed adjacent to the phrenic nerves to provide synchronized electrical stimulation of the diaphragm in mechanically ventilated patients.
Percutaneous phrenic nerve stimulation system (console and lead therapy set)
A therapy system composed of a stimulation console and temporary percutaneous multielectrode leads placed adjacent to the phrenic nerves to provide synchronized electrical stimulation of the diaphragm in mechanically ventilated patients.
Services
Collaboration with clinical sites to enroll and conduct multicenter randomized controlled IDE trials evaluating phrenic nerve stimulation to facilitate ventilator weaning.
Design and conduct of early clinical feasibility studies to assess lead placement, synchronization performance, and physiologic outcomes.
Collaboration with clinical sites to enroll and conduct multicenter randomized controlled IDE trials evaluating phrenic nerve stimulation to facilitate ventilator weaning.
Design and conduct of early clinical feasibility studies to assess lead placement, synchronization performance, and physiologic outcomes.
Expertise Areas
- Neuromodulation therapy for respiratory muscles
- ICU ventilation management and weaning
- Multicenter randomized controlled trial design and execution
- FDA IDE pathway and regulatory engagement
Key Technologies
- Electrical peripheral nerve stimulation
- Percutaneous multielectrode lead delivery (through‑the‑needle)
- Real‑time stimulation‑ventilator synchronization algorithms
- Diaphragm exercise-based therapy (non‑ventilatory stimulation)
News & Updates
Publication of a clinical trial protocol evaluating the pdSTIM System for weaning from mechanical ventilation.
The company has started a pivotal trial to evaluate the safety and efficacy of its neuromuscular stimulation device in ICU patients.
Funding round closed to support the company's pivotal clinical study.
The study demonstrated the safety and performance of the Percutaneous Electrical Phrenic Nerve Stimulation (PEPNS) System in ICU patients.
Received FDA breakthrough device designation to facilitate weaning patients from mechanical ventilation.
Received a foundational patent related to electrical stimulation for diaphragm function restoration.
Publication of a clinical trial protocol evaluating the pdSTIM System for weaning from mechanical ventilation.
The company has started a pivotal trial to evaluate the safety and efficacy of its neuromuscular stimulation device in ICU patients.
Funding round closed to support the company's pivotal clinical study.
The study demonstrated the safety and performance of the Percutaneous Electrical Phrenic Nerve Stimulation (PEPNS) System in ICU patients.
Received FDA breakthrough device designation to facilitate weaning patients from mechanical ventilation.
Received a foundational patent related to electrical stimulation for diaphragm function restoration.